Ligand Pharma (LGND) Tops Q1 EPS by 11c ; Offers Guidance
Tweet
Share
E-mailGet Alerts LGND Hot Sheet
Price: $274.88 --0%
EPS Growth %: +25.6%
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
OCCI, MAYS, CRMT, More
EPS Growth %: +25.6%
Financial Fact:
Total operating costs and expenses: 16.15M
Today's EPS Names:
OCCI, MAYS, CRMT, More
Join SI Premium – FREE
Ligand Pharma (NASDAQ: LGND) reported Q1 EPS of $1.33, $0.11 better than the analyst estimate of $1.22. Revenue for the quarter came in at $45.33 million versus the consensus estimate of $37.92 million.
GUIDANCE:
Ligand Pharma sees FY2025 EPS of $6.00-$6.25, versus the consensus of $6.11. Ligand Pharma sees FY2025 revenue of $180-200 million, versus the consensus of $191.3 million.
For earnings history and earnings-related data on Ligand Pharma (LGND) click here.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- AeroVironment restates quarterly financials, citing $89M goodwill error
- KeyBanc on Advanced Drainage Systems (WMS): 'nderappreciated Outgrowth'
- Stifel Reiterates Buy Rating on Crinetics (CRNX)
Create E-mail Alert Related Categories
Earnings, GuidanceRelated Entities
Earnings, Maynard Um, Mark Zuckerberg, ARKSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
